Filing Flows › Ocular Therapeutix (OCUL) › R&D spending
Ocular Therapeutix (OCUL) R&D spending by quarter
Ocular Therapeutix's R&D spending was $54.1M in Q2 2026 (second quarter 2026), -18% from Q1 2026. Over the last 7 quarters it ranged from $41.0M (Q4 2024) to $66.2M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $54.1M | -18% | +6% |
| Q1 2026 | $66.2M | +30% | +54% |
| Q4 2025 | $50.8M | -3% | +24% |
| Q3 2025 | $52.4M | +2% | — |
| Q2 2025 | $51.1M | +19% | — |
| Q1 2025 | $42.9M | +5% | — |
| Q4 2024 | $41.0M | — | — |
Q2 2026 at a glance
Ocular Therapeutix, Q2 2026: revenue $13.5M (+0.1% year over year), operating margin -609.3%, net loss $78.8M, operating cash flow −$67.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ocular Therapeutix's R&D spending?
Ocular Therapeutix's R&D spending was $54.1M in Q2 2026 (second quarter 2026), -18% from Q1 2026.
How has Ocular Therapeutix's R&D spending changed?
Over the last 7 quarters it ranged from $41.0M (Q4 2024) to $66.2M (Q1 2026).